Format
Sort by

Send to

Choose Destination

Search results

Items: 3

1.

Clinical Significance of Pancreatic Atrophy Induced by Immune-Checkpoint Inhibitors: A Case-Control Study.

Eshet Y, Baruch EN, Shapira-Frommer R, Steinberg-Silman Y, Kuznetsov T, Ben-Betzalel G, Daher S, Gluck I, Asher N, Apter S, Schachter J, Bar J, Boursi B, Markel G.

Cancer Immunol Res. 2018 Dec;6(12):1453-1458. doi: 10.1158/2326-6066.CIR-17-0659. Epub 2018 Oct 1.

PMID:
30275274
2.

Possible immune adverse events as predictors of durable response to BRAF inhibitors in patients with BRAF V600-mutant metastatic melanoma.

Ben-Betzalel G, Baruch EN, Boursi B, Steinberg-Silman Y, Asher N, Shapira-Frommer R, Schachter J, Markel G.

Eur J Cancer. 2018 Sep;101:229-235. doi: 10.1016/j.ejca.2018.06.030. Epub 2018 Aug 7.

PMID:
30096703
3.

Rheumatic manifestations among cancer patients treated with immune checkpoint inhibitors.

Lidar M, Giat E, Garelick D, Horowitz Y, Amital H, Steinberg-Silman Y, Schachter J, Shapira-Frommer R, Markel G.

Autoimmun Rev. 2018 Mar;17(3):284-289. doi: 10.1016/j.autrev.2018.01.003. Epub 2018 Jan 16.

PMID:
29341936

Supplemental Content

Loading ...
Support Center